The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of neoadjuvant chemotherapy (NCT) with the gamma secretase (GS) inhibitor RO4929097 in combination with paclitaxel (P) and carboplatin (C) in women with triple-negative breast cancer (TNBC).
Ewa Mrozek
No relevant relationships to disclose
Robert Wesolowski
No relevant relationships to disclose
Maryam B. Lustberg
No relevant relationships to disclose
Rachel M. Layman
No relevant relationships to disclose
Yonghua Ling
No relevant relationships to disclose
Larry J. Schaaf
No relevant relationships to disclose
Mitch A. Phelps
No relevant relationships to disclose
S. Percy Ivy
No relevant relationships to disclose
Michael R. Grever
No relevant relationships to disclose
Charles L. Shapiro
No relevant relationships to disclose